Publication | Open Access

Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses

AsthmaVersus OmalizumabAllergyMultiple DosesAllergy MedicinePharmacologyAllergenPharmacotherapyImmunotherapyMedicineDrug Allergy